[ Inside the business ]

CORZ stock analysis

CORZ · Core Scientific, Inc.

Finance services. Growing 187%. Loses 73¢ on every dollar.

Nothing unusual in its latest filings.

The future, in 7 questions

Priced in: 2.5× sales in 5 yrs. Evidence: sales +187% · loss growing.

01 What's priced in?2.5× sales in 5 yrs
Sales now$592M
Needed in 5 yrs$1.5B
Backlog$441M
02 Is the wave rising?No Radar technology matched

Not among the companies mentioning Radar's technologies most.

03 Will customers keep buying?Customer G: 100% of sales
Customer G 100%Customer J 100%Customer L 65%Customer F 31%Everyone else
Backlog $441M · 0.7× salesPrepaid $309MSales +187%, speeding up
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Loss growing: −73¢ per $1
'21'22'23'24'25−73¢
Before running costs: 1% → 12%
06 Can it fund itself?0.6 yrs of cash
05 yrs10+ yrs
Shares −2.3%/yrDebt $4.3B
07 What could break it?Nothing flagged

✓ All clear

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth speeding up.

Sales growth +45%, +109%, then +187% vs. a year ago. New filings show insiders buying.

What could go wrong

Red flags.

Debt is moderate. 2 red flags in its filings.

Speculative check

Not classified.

Not Self-funding because of: operating loss, net loss, current ratio under 1, and more. Cash runway: 0.6 years.

What they sell

Not broken out.

The filings don't split revenue by product in structured data.

Where each dollar goes

73¢ loss.

59¢ to make what it sells, 115¢ on research and overhead, nothing left over. Revenue $592M in the last 12 months.

Its market

No projection.

The government's 10-year projections don't cover its industry code.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Growth.

It earns cash, invests heavily, and still raises money to grow.

Earnings quality

Can't score.

Not available: some of the eight inputs aren't in the company's structured filings (common for banks, insurers and companies without a cost of goods line).

Competitive advantage

0 of 3 years.

Returns beat its 11.1% cost of capital in 0 of the last 3 years. Gross margin went from 16% to 12%.

Future bets

$4.4B committed.

Promised to suppliers, per its latest 10-Q.

All figures from Core Scientific, Inc.'s SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.